Effect of microRNA-145 on IL-1β-induced cartilage degradation in human chondrocytes  by Yang, Bo et al.
FEBS Letters 588 (2014) 2344–2352journal homepage: www.FEBSLetters .orgEffect of microRNA-145 on IL-1b-induced cartilage degradation
in human chondrocyteshttp://dx.doi.org/10.1016/j.febslet.2014.05.033
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Abbreviations: OA, osteoarthritis; Smad3, mothers against decapentaplegic
homolog 3; ECM, extracellular matrix; IL-1b, interleukin-1 beta
⇑ Corresponding author. Address: Department of Biomedical Materials Science,
School of Biomedical Engineering, Third Military Medical University, Gaotanyan
Street No. 30, Chongqing 400038, China.
E-mail address: shiwudong@gmail.com (S. Dong).Bo Yang a, Xia Kang b, Yan Xing a, Ce Dou c, Fei Kang c, Jianmei Li c, Yi Quan b, Shiwu Dong c,⇑
a Laboratory of Biomechanics, Department of Anatomy, Third Military Medical University, Chongqing, China
bDepartment of Orthopedics, Chengdu Military General Hospital, Chengdu, China
cDepartment of Biomedical Materials Science, School of Biomedical Engineering, Third Military Medical University, Chongqing, Chinaa r t i c l e i n f o
Article history:
Received 3 March 2014
Revised 22 April 2014
Accepted 15 May 2014
Available online 27 May 2014
Edited by Tamas Dalmay
Keywords:
Osteoarthritis
MicroRNA
MicroRNA-145
Interleukin-1 beta
Extracellular matrixa b s t r a c t
MicroRNA-145 has been shown to regulate chondrocyte homeostasis. It seems that miR-145 is impli-
cated in cartilage dysfunction in Osteoarthritis (OA). However, the functional role of miR-145 in
interleukin-1 beta (IL-1b)-induced extracellular matrix (ECM) degradation of OA cartilage has never
been clariﬁed. Here, we show that miR-145 expression increased in OA chondrocytes and in
response to IL-1b stimulation. We conﬁrm that mothers against decapentaplegic homolog 3
(Smad3), a key factor in maintaining chondrocyte homeostasis, is directly regulated by miR-145.
Modulation of miR-145 affects the expression of Smad3 causing a change of its downstream target
gene expression as well as IL-1b-induced ECM degradation in OA chondrocytes. This indicates that
miR-145 contributes to impaired ECM in OA cartilage probably in part via targeting Smad3.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction similar osteoarthritic phenotype resembling human OA is observedThe progressive destruction of articular cartilage is a major hall-
mark of osteoarthritis (OA). Although multiple factors are involved
in triggering OA, the cartilage destruction appears to be a result of
imbalance between extracellular matrix (ECM) synthesis and deg-
radation [1–3]. During OA pathogenesis, chondrocytes become
metabolically active and disrupt the equilibrium between anabolic
and catabolic effects, such that synthesis of aggrecan and type II
collagen is reduced and production of matrix-degrading enzymes
matrix metalloproteinase 13 (MMP-13) is enhanced [4]. In the
multiple molecular events involved in OA cartilage destruction,
transforming growth factor-b (TGF-b) signaling not only acts as a
principal inducer of cartilage ECM synthesis [5,6] and counteracts
the catabolic effectors [7]. Disruption of TGF-b signaling in chon-
drocytes apparently leads to degradation of cartilage ECM. For
example, the mice lack of responsiveness to TGF-b signaling in
skeletal tissues present progressive cartilage degeneration [8]. Ain the null mice for mothers against decapentaplegic homolog 3
(Smad3) [9], a key mediator of TGF-b signaling. Consistent with
this report, chondrocyte-speciﬁc reduction of Smad3 causes pro-
gressive cartilage degeneration due to elevating more production
of MMP-13 and repressing synthesis of type II collagen [10]. Fur-
thermore, Smurf2-transgenic mice appears spontaneously OA-like
phenotype via inducing phosphorylated Smad3 to degaration [11].
Notably, genetic variation of Smad3 has been found to be associ-
ated with human hip and knee OA in European populations [12].
These data indicate an essential role of Smad3 maintaining the bal-
ance between cartilage matrix synthesis and degradation.
MicroRNAs (miRNAs) are a class of non-coding small RNAs
that take part in regulating cellular processes such as cell
proliferation, apoptosis and differentiation [13,14]. Accumulating
evidence suggested that miRNAs are implicated in the pathogen-
esis of OA. The miRNAs potentially involved in OA have been
observed through using miRNA microarrays to compare miRNAs
expression between normal and OA human articular cartilage
[15–17]. Thereby, miRNAs functions for these factors causing an
imbalance between catabolic and anabolic effects in OA cartilage
warrant further studies. It is well known that inﬂammatory cyto-
kine Interleukin-1 beta (IL-1b), a major catabolic inducer, is
increased in OA joint tissues and contributes to the progression
of OA [2,18,19]. IL-1b induces increased production of proteases,
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sis of proteoglycan and collagens [20–22]. Recent studies demon-
strated that several miRNAs are implicated in the processes of OA
cartilage breakdown triggered by IL-1b, including miR-140 [23],
miR-27b [24], miR-146a [25], miR-9, miR-98 [16] and miR-558
[26]. Previous study showed miR-145 was up-regulated in
response to TGF-b1 in rat mesenchymal stem cells [27]. The ﬁnd-
ing implied that miR-145 is probably involved in TGF-b signaling.
The balance between IL-1b and TGF-b signaling is crucial for
chondrocytes homeostasis. For example, TGF-b counteracts IL-1b
up-regulation of MMP-13 and down-regulation of ECM-related
genes [28]. On the other hand, TGF-b-stimulated expression levels
of type II collagen and aggrecan were abrogated by IL-1b [29].
We have previously shown that miR-145 suppressed chondro-
genic differentiation of the murine cells by targeting SRY-related
high mobility group-Box gene 9 (Sox9) [30], a master positive reg-
ulator of chondrogenesis. Importantly, overexpression of miR-145
resulted in a decreased expression of cartilage ECM genes in human
chondrocytes [31]. It seems that miR-145 probably regulates the
cartilage dysfunction in OA. However, the functional role of
miR-145 in regulating metabolism of OA cartilage has never been
identiﬁed. In this study, our results indicate that the increased
expression of miR-145 in response to IL-1b contributes to impaired
ECM in OA chondrocytes, probably in part via targeting Smad3.2. Materials and methods
2.1. Specimen selection
OA articular cartilage was obtained from 11 patients with OA
(ages 56–74 years) who underwent knee-joint replacement sur-
gery. The patients with OA were diagnosed according to the Amer-
ican College of Rheumatology criteria and corresponded to
Kellgren–Lawrence OA grades III, and IV. Normal articular knee
cartilage was collected from 5 patients (ages 20–59 years) with
no history of OA or rheumatoid arthritis (RA) who underwent
amputation resulting from trauma. The specimen selection was
performed at Chengdu Military General Hospital with Ethical Com-
mittee approval and all patients provided informed consent.
2.2. Human chondrocytes isolation and culture
Cartilage specimens were separated and cut into small pieces.
Cartilage tissues for the direct isolation of miRNAs were milled in
liquid nitrogen and then extracted for total RNA using Rneasy
Fibrous Tissue mini Kit (Qiagen) according to the manufacturer’s
instructions. Cartilage pieces for cell culture were predigested with
trypsin (0.1%, w/v) (Sigma) for 30 min and collected to collagenase
II (0.15%, w/v) (Sigma) digests for 16 h at 37 C. The suspension
was passed through a 100-lm nylon cell strainer (BD Falcon) and
rinsed in DMEM (Hyclone) with 10% fetal bovine serum (FBS) (Gib-
co). Isolated chondrocytes seeded in T-75 culture ﬂasks in DMEM
supplemented with 10% FBS (v/v), 100 units/mL penicillin, and
100 lg/mL streptomycin (Gibco). The ﬁrst passage chondrocytes
were used for the following experiments. HEK293 cells (ATCC)
were cultured in DMEM-F12 containing 10% FBS. All cells were
incubated at 37 C with 5% CO2 in a humidiﬁed incubator. The cul-
ture medium was replaced every 2–3 days.
2.3. Transfection and luciferase assays
The agomir-145 (mimic), antagomir-145 (inhibitor) and their
negative controls were purchased from RiboBio. Agomir-145
(50 nM), antagomir-145 (150 nM) or their negative controls were
transfected, respectively, into OA chondrocytes at 80% conﬂuenceusing Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. After 24 h of transfection, cells were serum
starved for 12 h and then treated with IL-1b (5 ng/mL) (PeproTech)
for 24 h. Cells were harvested for subsequent experiments.
Smad3 SiRNA and their negative controls were purchased from
GenePharma. After validation of their inhibition efﬁcacy, selective
Smad3 SiRNA (150 nM) or negative control was co-transfected
with antagomir-145 (150 nM) in 6-well plate using Lipofectamine
2000.
For luciferase activity analysis, HEK293 cells were co-transfec-
ted with 500 ng of luciferase reporter constructs, and 10 pmol of
agomir-145 with 2 ll Lipofectamine 2000 in 24-well plate. After
24 h of transfection, luciferase assay was carried out through
dual-luciferase reporter assay system (Promega).
2.4. RNA extraction, reverse transcription and quantitative RT-PCR
Total RNA was extracted using TRIzol contained chondrocytes.
The 20% (v/v) Chloroform was added and centrifugation at 4 C.
The aqueous phase was transferred to fresh tubes and equal vol-
umes isopropyl alcohol was added. The mixture was stood for
one hour at 20 C and centrifugated. After washing the deposits
with 70% (v/v) alcohol, total RNA was extracted.
Generation of cDNA was performed by M-MLV Reverse Trans-
criptase kit (Promega). For miR-145 detection, reaction was per-
formed at 37 C for 60 min, 70 C for 10 min. For mRNA
detection, reaction was performed at 42 C for 60 min, 70 C for
10 min.
Reverse transcription was followed by quantitative RT-PCR with
a SYBR Green PCR Master Mix (ABI). The speciﬁc primers used for
the different mRNAs were listed in Table S1. The RT-PCR primers
including U6, hsa-miR-145, GAPDH were purchased from RiboBio.
GAPDH and U6 were used as internal controls. For miR-145 detec-
tion, the cDNA samples were incubated at 95 C for 3 min, followed
by 40 cycles at 95 C for 10 s and 60 C for 20 s, 70 C for 10 s. For
mRNA detection, the cDNA samples were incubated at 95 C for
3 min, followed by 40 cycles at 95 C for 10 s and 60 C for 30 s,
70 C for 10 s. All quantitative RT-PCR reactions were performed
in the PCR System 7500 (ABI). Data were analyzed using the 2DD-
Ct method.
2.5. Generation of luciferase reporter constructs
The pmiR-RB-REPORT luciferase reporter (RiboBio) was used as
a vehicle. The full length Smad3 30UTR was obtained via PCR using
primers 1 (Table S2), and then cloned into the XhoI/NotI site of the
luciferase reporter to generate pmiR-Smad3. Reporter constructs
containing the mutated seed sites within pmiR-Smad3 (pmiR-
Smad3 mut1, pmiR-Smad3 mut2) were obtained via PCR mutagen-
esis. Brieﬂy, the pmiR-Smad3 vector as a template was ampliﬁed
using primers 2 (Table S2). Both PCR product and vehicle were
digested with speI and NotI (Takara), puriﬁed and then cloned into
the digested vehicle to generate pmiR-Smad3 mut1. Next, the
pmiR-Smad3 vector as a template was ampliﬁed using two pairs
primers, respectively (primers 3, 4) (Table S2). PCR products were
spliced by overlap extension PCR using primers 5 (Table S2). Both
PCR product and vehicle were digested with BsteII and NotI, puri-
ﬁed and then cloned into the digested vehicle to generate pmiR-
Smad3 mut2. All of the construct were sequenced to veriﬁcation.
2.6. Western blot
The cell lysates were extracted with lysis buffer. The equal pro-
tein samples were mixed with 5 sample buffer (Beyotime) and
boiled. The samples were transferred on PVDF membrane
(Millipore) by using the semi-dry transfer method. After blocking
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with anti-Smad3 (Abcam) or anti-b-actin antibody (Santa Cruz)
overnight at 4 C. b-Actin acted as an internal control. After wash-
ing by TBST, the blots were incubated with a horseradish peroxi-
dase-conjugated secondary antibody (Santa Cruz) at room
temperature for 1 h. The blots were visualized by Femto (Pierce)
following the manufacturer’s instructions.
2.7. Sulfated glycosaminoglycans (GAGs) analysis
The chondrocytes were digested at 65 C for 3 h in a 0.5% (v/v)
papain solution (Sigma). The supernatant of papain digests were
detected by Blyscan sulfated Glycosaminoglycan assay kit (Biocol-
or) according to the manufacturer’s instructions. The glycosamino-
glycan standards were used to produce a calibration curve. For the
quantiﬁcation of GAGs content, the corresponding supernatant of
papain digests was detected by Picogreen dsDNA kit (Invitrogen)
following the manufacturer’s instructions. The lambda DNA stan-
dards were used to produce a calibration curve. GAGs content
was normalized according to the DNA content. The absorbance or
ﬂuorescence was measured by SpectraMax M2 microplate spectro-
ﬂuorometer (Molecular Devices).
2.8. Elisa
The level of MMP-13 secreted by chondrocytes in the culture
supernatants was quantiﬁed using MMP-13 ELISA kit (CUSABIO)
following the manufacturer’s instructions. The MMP-13 concentra-
tion was calculated using a standard curve.
2.9. Immunoﬂuorescence
Cultured cells were rinsed in PBS and ﬁxed with 4% paraformal-
dehyde for 15 min. After rinsing with PBS, these samples were cov-
ered with 10% goat serum for 60 min and then incubated with anti-
type II collagen (Abcam) overnight at 4 C. After rinsing with PBS,
these samples were incubated with goat anti-rabbit IgG conjugated
Alexa Fluor 647 (Invitrogen) for 30 min at 37 C. Next, after rinsing
in dark, these samples were incubated with 0.1 lg/mL DAPI for
3 min. The PBS replaced primary antibodies as negative controls.
Images were collected by a laser confocal microscope LSM780NLO
(Zeiss).Fig. 1. MiR-145 is up-regulated in OA cartilage and chondrocytes and in response to IL-1
(n = 11) were determined by quantitative RT-PCR. (B) Relative expression of miR-145 in n
The data are presented in a dot plot where every dot resembles the value of one donor. Th
chondrocytes (n = 6) were treated with IL-1b for 24 h. Relative expression of miR-145 w
chondrocytes untreated with IL-1b was set to one, as control. U6 was used as internal c2.10. Statistical analysis
Data are expressed as the mean ± S.E.M. Statistical comparisons
were made between two groups with the two-tailed paired t-test.
A value of P < 0.05 was considered signiﬁcant unless otherwise
described.3. Results
3.1. MiR-145 is up-regulated in OA cartilage and chondrocytes and in
response to IL-1b-stimulated
To assess the potential effect of miR-145 in the OA processes,
we examined its expression level in normal and OA articular car-
tilage. The expression of miR-145 was signiﬁcantly up-regulated
in OA articular cartilages tissues and chondrocytes compared
with normal groups (Fig. 1A and B). Subsequently, we determined
the expression of miR-145 in IL-1b-stimulated human chondro-
cytes. As expected, miR-145 expression was signiﬁcantly
increased in normal and OA chondrocytes treated by IL-1b
(Fig. 1C).
3.2. Modulation of miR-145 effects IL-1b-induced inhibition of
aggrecan and type II collagen synthesis in OA chondrocytes
To explore whether miR-145 affected the IL-1b-induced
matrix degradation, we transfected either agomir-145 or antago-
mir-145 into the OA chondrocytes and then stimulated the cells
with IL-1b. IL-1b-stimulation resulted in a signiﬁcant down-reg-
ulation of aggrecan (ACAN) and type II collagen (Col2a1) expres-
sion. Overexpression of miR-145 aggravates IL-1b-induced down-
regulation of ACAN and Col2a1 expression. On the contrary,
repression of miR-145 signiﬁcantly inhibited IL-1b-induced
decrease of ACAN and Col2a1 mRNA expression (Fig. 2A and
B). Furthermore, we evaluated whether modulation of miR-145
regulated type II collagen content synthesized in OA chondro-
cytes by immunoﬂuorescence staining. In accordance with the
change of Col2a1 mRNA, overexpression of miR-145 resulted in
a more decrease of ﬂuorescence intensity upon stimulation with
IL-1b and repression of miR-145 increased ﬂuorescence intensity
(Fig. 2C).b-stimulated. (A) Relative expression of miR-145 in normal (n = 5) and OA cartilages
ormal (n = 5) and OA chondrocytes (n = 6) were determined by quantitative RT-PCR.
e mean value of the samples is indicated by a line. (C) Human normal (n = 5) and OA
ere determined by quantitative RT-PCR. The relative expression level of miR-145 in
ontrol. Data are represented as mean ± S.E.M. ⁄P < 0.05.
Fig. 2. Modulation of miR-145 effects IL-1b-induced inhibition of aggrecan and type II collagen synthesis in OA chondrocytes. Relative expression of (A) Col2a1and (B) ACAN
mRNA in OA chondrocytes (n = 6) transfected with agomir-145, antagomir-145 or their negative control at 24 h after IL-1b stimulation were determined by quantitative RT-
PCR. The relative expression level of miR-145 in OA chondrocytes untreated with IL-1b and non-transfected was set to one, as control1. The chondrocytes treated with IL-1b
and non-transfected was indicated as control2. GAPDH was used as internal control. Data are represented as mean ± S.E.M. ⁄P < 0.05. (C) The type II collagen expression in OA
chondrocytes (n = 6) transfected with agomir-145, antagomir-145 or their negative control at 24 h after IL-1b stimulation were determined by immunoﬂuorescence staining.
Scale bars = 20 lm.
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degradation
To analyze the effect of miR-145 on the proteoglycan content, a
dimethylmethylene blue (DMMB) spectrophotometric analysis
was performed to determine the content of GAGs. As shown in
Fig. 3A, overexpression of miR-145 leaded to fewer GAGs concen-
trations in OA chondrocytes stimulated with IL-1b. On the other
hand, the IL-1b-induced degradation of GAGs was recovered by
suppression of miR-145 (Fig. 3A). Degenerative changes in OA car-
tilage matrix were probably resulted from enhanced catabolic fac-
tors, rather than reduced anabolic factors. MMP-13, as the major
collagenase contributing to the catabolic processes in OA, cleaves
key extracellular matrix constituents including type II collagen
and aggrecan. Thus, we used quantitative RT-PCR and ELISA to
examine the expression change of MMP-13 mRNA and secreted
MMP-13 protein in OA chondrocytes, which were transfected with
either agomir-145 or antagomir-145 and then stimulated withIL-1b. Overexpression of miR-145 resulted in an increased expres-
sion of MMP-13 mRNA and protein upon stimulation with IL-1b
(Fig. 3B and C). Conversely, inhibition of miR-145 made a contrary
effect (Fig. 3B and C).
3.4. MiR-145 directly targets Smad3
To elucidate how miR-145 effects IL-1b-induced ECM degrada-
tion of OA chondrocytes, we predict the target genes of miR-145
through Pictar [32] and Targetscan [33]. We found that Smad3,
playing a key role in maintaining the balance of anabolic and cat-
abolic processes, is a putative target gene of miR-145. Smad3 30-
UTR contains two putative miR-145 seed sites (Fig. 4A). We applied
the luciferase assay to identify these putative seed sites. Co-trans-
fection of agomir-145 with pmiR-Smad3 resulted in a signiﬁcant
suppression of luciferase activity (Fig. 4B). Moreover, the suppres-
sion effect occurred in a dose dependent manner (Fig. 4C). Muta-
tion of the seed site located in 1397–1404 of SMAD3 30 UTR
Fig. 3. Modulation of miR-145 effects IL-1b-induced cartilage matrix degradation. (A) GAGs (normalized for the DNA content) concentrations, (B) relative expression of MMP-
13 mRNA and (C) expression level of secreted MMP-13 protein in OA chondrocytes (n = 6) transfected with agomir-145, antagomir-145 or their negative control at 24 h after
IL-1b stimulation were determined by DMMB method, quantitative RT-PCR, and ELISA, respectively. The chondrocytes untreated with IL-1b and non-transfected was set as
control1. The chondrocytes treated with IL-1b and non-transfected was indicated as control2. GAPDH was used as internal control. Data are represented as mean ± S.E.M.
⁄P < 0.05.
Fig. 4. MiR-145 directly targets Smad3. (A) A schematic shows that the 30-UTR of Smad3 contains two putative miR-145 seed sites. (B) agomir-145 or its negative control was
co-transfected with the pmiR-RB-REPORT constructs containing full length Smad3 30UTR (indicated as WT) and two mutated seed sites within pmiR-Smad3 (indicated as
MUT1, MUT2), respectively, into HEK293 cells. (C) HEK293 cells were co-transfected with pmiR-RB-REPORT constructs containing full length Smad3 30UTR together with
varying amounts of agomir-145, as indicated. All cells (B and C) were harvested at 48 h after transfection, and then luciferase activities were measured. Data was represented
as mean ± S.E.M. ⁄P < 0.05.
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luciferase activity. However, mutation of the seed site located in
3925–3931 of SMAD3 30 UTR (pmiR-Smad3 mut2) did not affectdecreased luciferase activity (Fig. 4B). Our data indicated that
miR-145 could target Smad3 by binding the seed site located in
1397–1404 of SMAD3 30 UTR.
Fig. 5. Regulation of the expression of Smad3 by miR-145 in IL-1b-stimulated OA chondrocytes. (A) Relative expression of miR-145 and (B) Smad3 mRNA in OA chondrocytes
(n = 6) chondrocytes stimulated with IL-1b for 6, 12 and 24 h were determined by quantitative RT-PCR. The relative expression level of miR-145 or Smad3 mRNA in OA
chondrocytes untreated with IL-1bwas respectively set to one, as control. U6 or GAPDH were used as internal control for miR-145 or Smad3 detection, respectively. (C and D)
OA chondrocytes (n = 5) were transfected with agomir-145, antagomir-145 or their negative control at 24 h after IL-1b stimulation, and then relative expression level of (C)
mRNA and (D) protein of Smad3 were measured by quantitative RT-PCR and Western blot, respectively. The chondrocytes non-transfected was set as control. Data was
represented as mean ± S.E.M. ⁄P < 0.05.
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An inverse correlation between miR-145 and Smad3 expression
was observed. IL-1b stimulation signiﬁcantly induced miR-145
expression at 12 and 24 h and suppressed Smad3 expression in a
time-dependent manner in OA chondrocytes (Fig. 5A and B). Sub-
sequently, Smad3 expression at mRNA and protein levels was
assessed in the OA chondrocytes transfected with either agomir-
145 or antagomir-145. The results showed that overexpression of
miR-145 decreased Smad3 expression. Conversely, inhibition of
miR-145 increased Smad3 expression at both mRNA and protein
levels in OA chondrocytes (Fig. 5C and D).
3.6. Silencing of miR-145 attenuates IL-1b-induced cartilage matrix
degradation in OA chondrocytes via targeting Smad3
To further conﬁrm the role of Smad3 in the miR-145 mediated
ECM degradation in response to IL-1b, two Smad3-responsive
endogenous target genes including plasminogen activator inhibi-
tor-1 (PAI-1) and tissue inhibitor of metalloproteinase-3 (TIMP-3)
were assessed by examining the mRNA expression. Our results
showed that IL-1b reduced mRNA expression of PAI-1 and TIMP-
3. Importantly, the decrease of PAI-1 and TIMP-3 by IL-1b waspartly reversed by inhibition of miR-145 (Fig. 6A). These results
indicate that miR-145 can regulate the expression of Smad3 down-
stream genes in OA chondrocytes. Secondly, we co-transfected OA
chondrocytes with antagomir-145 along with Smad3 siRNA and
then stimulated with IL-1b. The effect that silence of miR-145
attenuates IL-1b-induced down-regulation of Col2a1, PAI-1,
TIMP-3 and up-regulation of MMP-13 mRNA expression was
blocked by added Smad3 siRNA (Fig. 6A and B). However, co-trans-
fection with antagomir-145 and Smad3 siRNA had no appreciable
effect on expression of ACAN mRNA compared with transfection
with antagomir-145 alone (Fig. 6B). Although Smad3 siRNA had
no inﬂuence on mRNA expression of ACAN, GAGs assay showed
that co-transfection with antagomir-145 and Smad3 siRNA
decreased GAGs content compared with transfection with antago-
mir-145 alone (Fig. 6C).
4. Discussion
In this study, we identiﬁed that miR-145 expression is signiﬁ-
cantly up-regulated in OA chondrocytes and also in response to
IL-1b stimulation. It implied that miR-145 is possibly involved in
OA pathogenesis. Modulation of miR-145 efﬁciently effected
IL-1b-induced ECM degradation in OA chondrocytes, as evidenced
by that inhibition of miR-145 was able to reverse IL-1b-induced
Fig. 6. Silencing of miR-145 attenuates IL-1b-induced cartilage matrix degradation in OA chondrocytes via targeting Smad3. Relative expression of (A) PAI-1, TIMP-3, (B)
Col2a1, MMP-13 and ACAN mRNA in OA chondrocytes (n = 5) transfected with antagomir-145 alone or in combination with Smad3 siRNA at 24 h after IL-1b stimulation were
determined by quantitative RT-PCR. The relative expression level of corresponding mRNA in cells non-transfected with antagomir control and siRNA control and untreated
with IL-1b stimulation was set to one, as control. (C) GAGs (normalized for the DNA content) concentrations in OA chondrocytes (n = 5) transfected with antagomir-145 alone
or in combination with Smad3 siRNA at 24 h after IL-1b stimulation were determined by DMMB method. The chondrocyte non-transfected with antagomir control and siRNA
control and untreated with IL-1b stimulation was set as control. GAPDH were used as internal control. Data was represented as mean ± S.E.M. ⁄P < 0.05.
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decrease IL-1b-induced production of MMP-13. Moreover, we con-
ﬁrmed that Smad3, an essential factor for chondrocyte homeosta-
sis, was directly regulated by miR-145.
IL-1b plays a pivotal role in cartilage degradation during OA
development [18–22]. Several miRNAs have been identiﬁed partic-
ipating in the processes of disrupted cartilage homeostasis in
response to IL-1b. Treatment of human chondrocytes with IL-1b
suppresses expression of miR-140 [23]. MiR-140 can also suppress
the TGFb pathway through repressing the expression of Smad3 on
the protein level [34]. Interestingly, a recent research found thatSmad3, as a repressor, regulates the expression of miR-140 by
physically binding with miR-140 in OA chondrocytes [35]. These
results indicate that the interaction between miR-140 and Smad3
may form a negative feedback loop in OA chondrocytes.
It has been found that miR-145 is important to maintain the dif-
ferentiation status of vascular smooth muscle cells and regulate
the self-renewal program of embryonic stem cells [36,37]. In OA,
miRNA microarray data demonstrate that miR-145 is signiﬁcantly
up-regulated in human OA chondrocytes from four patients [17].
Here, we conﬁrmed that miR-145 is increased in human OA chon-
drocytes and IL-1b enhanced miR-145 expression. Collectively, it
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drocytes in response to IL-1b may contribute to the imbalance of
anabolic–catabolic effect in OA cartilage.
Our results demonstrated that miR-145, as a positive effector in
IL-1b-induced catabolic events, promotes degradation of OA carti-
lage ECM. Overexpression of miR-145 aggravated IL-1b-induced
down-regulation of aggrecan, type II collagen, GAGs, and further
decrease IL-1b-induced production of MMP-13. Conversely, inhibi-
tion of miR-145 reverse above catabolic effect resulted from IL-1b
treatment. Previous studies have shown that a master regulator for
chondrocytes metabolism, Sox9, is a target gene of miR-145
[30,31]. Overexpression of Sox9 could restore the expression levels
of proteoglycans and type II collagen in OA articular cartilage [38].
It is perfectly reasonable to assume that the positive effect of miR-
145 on IL-1b-induced catabolic events that should be mediated by
Sox9. However, an important character of miRNAs is that one sin-
gle miRNA can regulate various target genes, owing to its short
seed match and imperfect base-pairing between miRNAs and their
targets. Thus, we hypothesize that miR-145may regulate other tar-
get genes, besides Sox9, to modulate IL-1b responses in OA
chondrocytes.
We identiﬁed that Smad3 is directly regulated by miR-145 via
binding only one of the predicted seed sites, resulting in the sup-
pression of Smad3 expression on both mRNA and protein level.
Additionally, we observe an inverse correlation between miR-145
and Smad3 expression in OA chondrocytes stimulated with IL-1b.
These results indicate that Smad3 as another target genes of
miR-145, probably mediates the effect of IL-1b responses in OA
cartilage.
Smad3 plays an essential role to maintain chondrocytes homeo-
stasis. In articular cartilage, TGF-b signalling through SMAD3-
dependent mechanisms maintains chondrocytes homeostasis by
repressing Runx2-inducible MMP-13 expression [10]. Interest-
ingly, Smad3 can physically interact with Sox9, forming a complex
that can enhance CBP/p300, transcriptional coactivators of Sox9,
recruitment and then promote the expression of Col2a1 [39]. These
experimental evidences suggest that miR-145 aggravate IL-1b-
induced down-regulation of type II collagen, GAGs concentration
while up-regulation of MMP-13 expression, in part due to the inhi-
bition of Smad3 by miR-145. We also reported two Smad3 target
genes associated to OA cartilage degradation, PAI-1 and TIMP-3,
can be regulated by miR-145 in OA chondrocytes stimulated with
IL-1b. Moreover, the effect of miR-145 inhibitor preventing IL-1b-
induced down-regulation of Col2a1, PAI-1, TIMP-3 and up-regula-
tion of MMP-13 mRNA expression, was broken by added Smad3
siRNA. However, Smad3 siRNA did not affect the change of ACAN
mRNA expression. Considering that ACAN is a downstream gene
of Sox9, it suggested that miR-145 indirectly regulating ACAN
expression is not mediated by Smad3 but Sox9. Although the
expression of ACAN mRNA was unchanged, decreased GAGs con-
tent was observed. Both PAI-1 and TIMP-3 are important cartilage
endogenous inhibitors to catabolic protease, including Plasmin,
MMPs and a disintegrin and metalloproteinases (ADAMs) [40,41].
It is probably attributable to knock-down Smad3 resulting in
increased expression of MMP-13 and decreased gene expression
of inhibitors to catabolic protease, such as PAI-1 and TIMP-3. Taken
together, we found that miR-145 acts as a positive regulator of
IL-1b-induced metabolism disturbance of human chondrocytes,
at least in part, via inhibiting Smad3 expression. As Smad3 acti-
vates Sox9-dependent transcription on chromatin [42], most of
the effects of miR-145 may directly or indirectly due to Sox9. The
synergistic effect of Smad3 and another miR-145 target gene
Sox9 may make the miR-145-mediated modulation of IL-1b
response in OA chondrocytes more efﬁcient.
Besides OA, miR-145 expression correlates with cardiovascular
diseases in human [36,43,44]. For instance, the expression ofmiR-143/145 in aorta obtained from patients having an aortic
aneurism is markedly decreased [36]. In the aortic wall of the
patients with aneurysms-osteoarthritis syndrome, increased
expression of Smad3 and enhanced TGF-b signaling has been found
[45]. It would be interesting to investigate the role of miR-145-
mediated TGF-b/Smad3 signaling in aortic aneurism.
In conclusion, our ﬁndings suggest that miR-145 directly regu-
lates the expression of Smad3, contributing to IL-1b-induced chon-
drocytes ECM degradation. Further studies of miR-145may present
new insights into disease mechanisms and therapeutic approach in
OA.
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